Prescribing information (external link)
LEQVIO® (inclisiran) is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:1
in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or
alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.
The effect of LEQVIO® on cardiovascular morbidity and mortality has not yet been determined.1
For full safety information, please refer to the LEQVIO® Summary of Product Characteristics.
LEQVIO® resources
Explore our growing repository of resources designed to provide useful information on LEQVIO® and other relevant topics for healthcare professionals (HCPs) treating eligible patients with atherosclerotic cardiovascular disease.
Patient’s guide to LEQVIO®
Patient’s guide to LEQVIO®
Please note that this material should only be shared with patients for whom the decision to prescribe LEQVIO® has already been made.
This downloadable PDF can be shared with your LEQVIO® patients to provide them with further information on their condition and useful information regarding taking LEQVIO®.
Please do not share this web page directly with patients; instead, please direct them to the patient portal.
Please get in touch with us to speak to one of our Novartis representative
HCP, healthcare professional; LDL-C, low-density lipoprotein cholesterol.
References
LEQVIO® Summary of Product Characteristics.
UK | January 2026 | FA-11570143
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.
